{"id":390671,"date":"2018-05-21T00:00:00","date_gmt":"2018-05-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0005-2018-biopharma-chronic-obstructive-pulmonary-disease-patient-profiler-us-2018\/"},"modified":"2026-05-02T23:37:38","modified_gmt":"2026-05-02T23:37:38","slug":"paprim0005-2018-biopharma-chronic-obstructive-pulmonary-disease-patient-profiler-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0005-2018-biopharma-chronic-obstructive-pulmonary-disease-patient-profiler-us-2018\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Patient Profiler | US | 2018"},"content":{"rendered":"<p>The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim\u2019s Spiriva, AstraZeneca\u2019s Tudorza), LABA\/ICSFDCs (e.g., GlaxoSmithKline\u2019s Advair and Breo, AstraZeneca\u2019s Symbicort, Merck\u2019s Dulera [off-label in COPD]), and LABA\/LAMAs (e.g., GlaxoSmithKline\u2019s Anoro, Boehringer Ingelheim\u2019s Stiolto, AstraZeneca\u2019s Bevespi, Sunovion\u2019s Utibron) compete for a share of the maintenance market. Likewise, several short-acting inhaled therapies contend for a share of the acute COPD market, (e.g., Teva\u2019s ProAir, GlaxoSmithKline\u2019s Ventolin, Boehringer Ingelheim\u2019s Combivent). The market is expected to become even more competitive in the next several years, given the recent and upcoming approvals of triple LABA\/LAMA\/ICS combinations (e.g., GlaxoSmithKline\u2019s Trelegy), the recent and upcoming approvals of additional nebulized LAMAs, and the potential launch of the first COPD biologics, making brand differentiation and understanding of key patient characteristics even more critical for marketers.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>What are the demographic characteristics and clinical profiles of COPD patients receiving maintenance treatment with LABA\/ICSFDCs, LAMAs, and LABA\/LAMAFDCs?<\/li>\n<li>What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for COPD?<\/li>\n<li>How do patient cohorts for COPD compare in care utilization and outcomes (physician visits and other healthcare encounters)?<\/li>\n<li>What type of insurance do COPD patients have?<\/li>\n<li>What are the reimbursed and out-of-pocket costs?<\/li>\n<li>What provider specialties are associated with COPD patient claims?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Patient Profiler <\/em>provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG\u2019s comprehensive real-world data (RWD) repository.<\/p>\n<p><strong>Markets<\/strong><strong> covered:<\/strong> United States<\/p>\n<p><strong>Real World Data: <\/strong>U.S. electronic health records and claims data.<\/p>\n<p><strong>Key drugs covered:<\/strong> Spiriva, Tudorza, Incruse, Brovana, Advair, Symbicort, Dulera, Breo, Anoro, Stiolto, Utibron, Bevespi, Combivent, ProAir, Ventolin<\/p>\n<p><strong>Key analysis provided: <\/strong><\/p>\n<ul>\n<li>Patient demographics.<\/li>\n<li>Disease-specific lab tests and values.<\/li>\n<li>Risk factors and comorbidities.<\/li>\n<li>Coprescribing and adjunct therapy prescribing for comorbid conditions.<\/li>\n<li>Type of insurance and reimbursement\/cost analysis.<\/li>\n<li>Utilization of care and physician and prescriber demographics.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390671","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390671\/revisions"}],"predecessor-version":[{"id":393795,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390671\/revisions\/393795"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}